Pharming Group N.V. was registered as a private limited liability company under the laws of the Netherlands on November 11, 1988 and restructured into a public company in 1997. The company is a global biotechnology company focused on the development and commercialization of therapies for rare and ultra-rare diseases, with a focus on immunology and genetic diseases. 

Pharming is a commercial-stage biotech with two approved products and an interesting late-stage pipeline. The company's value proposition is built on three pillars: its rare disease franchise, which includes approved products for hereditary angioedema and paroxysmal nocturnal hemoglobinuria; its innovative clinical development pipeline, which includes two potentially transformative late-stage assets; and its focus on improving patient access to its products. Pharming's Q2/2026 earnings highlighted the company's progress in advancing its pipeline, with several upcoming clinical and regulatory milestones expected to drive growth in the coming months.

Pharming Group

Pharming's Rare-Disease Franchise Faces Challenges Despite Late-Stage Pipeline

Pharming Group will participate in the H.C. Wainwright 28th Annual Global Investment Conference and the Morgan Stanley 24th Annual Global Healthcare Conference in September. CEO Fabrice Chouraqui will present on September 14 at the H.C. Wainwright conference, and a live webcast will be available on Pharming's website. The company's investor relations team can be contacted for more information or to schedule one-on-one meetings with management. Pharming is a global biopharmaceutical company focused on rare, debilitating, and life-threatening diseases.

Pharming Group to Present at Investor Conferences in September

Pharming Group will participate in two investor conferences in September: H.C. Wainwright 28th Annual Global Investment Conference on September 14 and Morgan Stanley 24th Annual Global Healthcare Conference on September 15. Pharming's CEO, Fabrice Chouraqui, will present at the H.C. Wainwright conference. For more information, contact Pharming's Investor Relations team at investor@pharming.com.

Pharming to Present at Investor Conferences in September

Pharming Group N.V. announced that its management will participate in the H.C. Wainwright 28th Annual Global Investment Conference and Morgan Stanley 24th Annual Global Healthcare Conference in September. Fabrice Chouraqui, CEO, will present at the H.C. Wainwright conference on September 14. For more information, contact Pharming's Investor Relations team at investor@pharming.com. Pharming is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases.

Morgan Stanley

Pharming Group N.V. to Present at H.C. Wainwright and Morgan Stanley Conferences

On September 1, 2026, at 15:00, Pharming Group's 15-minute chart exhibited a KDJ Death Cross and a Bearish Marubozu pattern, indicating a shift in momentum towards the downside. This suggests that the stock price is poised to decrease further, as sellers dominate the market and bearish momentum is likely to persist.On September 1, 2026, at 15:00, Pharming Group’s 15-minute chart displayed a KDJ Death Cross and a Bearish Marubozu pattern, signaling a potential shift in momentum toward the downside. These technical indicators suggest that selling pressure has intensified, with bearish sentiment dominating the market and potentially <a href="https://www.google.com/goto?url=CAESmgEB6zswFVXrdJLKuY6_UplFiGLARUMl_NdJm4Ng9VO096KnvUDLdfNL_IZ5a0DTW8TSwtwoa1yQIcUexyQHpmgcQgHi3WACF5Eh27JX3H7to4RHmmU1zX_iqtzocboVjg3UKAkbKEzzpMNYg2UfDGLXIiePN-cfp0q7inkhiPidDr7pSVniYU6xylEc994D0TgnKQSJQffxXEVj">driving the stock price lower</a>.The stock has already experienced a 26.76% decline over the past 30 days, reflecting broader investor concerns following the company’s <a href="https://www.google.com/goto?url=CAESmgEB6zswFVXrdJLKuY6_UplFiGLARUMl_NdJm4Ng9VO096KnvUDLdfNL_IZ5a0DTW8TSwtwoa1yQIcUexyQHpmgcQgHi3WACF5Eh27JX3H7to4RHmmU1zX_iqtzocboVjg3UKAkbKEzzpMNYg2UfDGLXIiePN-cfp0q7inkhiPidDr7pSVniYU6xylEc994D0TgnKQSJQffxXEVj">revised 2026 revenue guidance</a> and weaker-than-expected half-year results. The guidance cut, which reduced projected revenue by US$30 million, has raised questions about the company’s ability to meet long-term growth expectations. Despite a narrative suggesting the stock is undervalued at €0.88 compared to an estimated fair value of €2.36, the <a href="https://www.google.com/goto?url=CAESmgEB6zswFVXrdJLKuY6_UplFiGLARUMl_NdJm4Ng9VO096KnvUDLdfNL_IZ5a0DTW8TSwtwoa1yQIcUexyQHpmgcQgHi3WACF5Eh27JX3H7to4RHmmU1zX_iqtzocboVjg3UKAkbKEzzpMNYg2UfDGLXIiePN-cfp0q7inkhiPidDr7pSVniYU6xylEc994D0TgnKQSJQffxXEVj">recent technical and fundamental developments</a> underscore the risks ahead.Analysts note that while RUCONEST continues to perform well in its niche market, delays in label expansions or increased competition could further pressure revenue and earnings. Investors are advised to monitor both technical signals and company-specific developments as the stock remains volatile.

PHAR News